Details

Autor(en) / Beteiligte

• Hata, Tae
• Sakaguchi, Chikara
• Hirano, Keita
• Kobe, Hiroshi
• Ishida, Masaki
• Nakano, Takayuki
• Tachibana, Yusuke
• Tamiya, Nobuyo
• Shiotsu, Shinsuke
• Takeda, Takayuki
• Yamada, Tadaaki
• Yokoyama, Toshihide
• Tsuchiya, Michiko
• Nagasaka, Yukio

Titel

Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study

Ist Teil von

• Journal of cancer research and clinical oncology, 2023-06, Vol.149 (6), p.2475-2482

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose The effect of immuno-chemotherapy on patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic mutations remains poorly understood. This study aimed to characterize the efficacy of immuno-chemotherapy and determine the optimal treatment strategy for such patients. Methods We conducted this retrospective cohort study on patients with NSCLC harboring oncogenic driver alterations and treated with an immune checkpoint inhibitor combined with chemotherapy at five institutions. The clinical characteristics and outcomes of immuno-chemotherapy for NSCLC with oncogenic mutations in a real-world setting were analyzed. Results Among 846 patients diagnosed with advanced or recurrent NSCLC between April 2017 and April 2021, 43 patients with oncogenic mutations were treated with immuno-chemotherapy. The median age of patients was 68 (range 44–78) years; 42% of patients never smoked, and adenocarcinoma was the most common histology (95%). In patients with KRAS mutations ( n  = 10) or PD-L1 expression of 50% or greater ( n  = 10), the disease control rate was 100%. The median progression-free survival (PFS) was 5.4, 6.3, and 8.9 months in patients harboring mutations in EGFR , KRAS , and other genes, respectively ( P  = 0.22). Patients with PD-L1 expression of 50% or greater had significantly longer median PFS than patients with PD-L1 expression of less than 50% (16.4 vs. 5.1 months; P  = 0.001). Two patients experienced grade 3 immuno-related adverse events. Conclusion Immuno-chemotherapy has a clinical benefit and is safe for patients with oncogenic mutations. Notably, patients with PD-L1 expression of 50% or more experience greater benefit from immuno-chemotherapy than those with PD-L1 expression of less than 50%.